We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
- Authors
Gulyás, Katalin; Horváth, Ágnes; Végh, Edit; Pusztai, Anita; Szentpétery, Ágnes; Pethö, Zsófia; Váncsa, Andrea; Bodnár, Nóra; Csomor, Péter; Hamar, Attila; Bodoki, Levente; Bhattoa, Harjit Pal; Juhász, Balázs; Nagy, Zoltán; Hodosi, Katalin; Karosi, Tamás; FitzGerald, Oliver; Szücs, Gabriella; Szekanecz, Zoltán; Szamosi, Szilvia
- Abstract
Objectives: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with generalized and localized bone loss. We conducted a comprehensive study using imaging (dual-energy X-ray absorptiometry, DXA) and laboratory biomarkers in order to determine bone health and to study the effects of anti-tumor necrosis factor (TNF) biologics in RA and AS. Patients and methods: Thirty-six RA and 17 AS patients undergoing 1-year etanercept (ETN) or certolizumab-pegol (CZP) therapy were studied. Bone density was assessed by DXA at baseline and after 12 months. Serum C-reactive protein (CRP), calcium, phosphate, parathyroid hormone (PTH), vitamin D3, osteocalcin, procollagen type I N-propeptide (P1NP), C-terminal telopeptide (βCTX), osteoprotegerin, sclerostin (SOST), Dickkopf-1 (DKK-1), soluble receptor activator nuclear kappa B ligand (sRANKL), and cathepsin K (cathK) levels were determined at baseline and after 6 and 12 months. Results: TNF-α inhibition was clinically effective. Anti-TNF-α halted further bone loss over 1 year. In general, anti-TNF therapy significantly increased P1NP, SOST levels, and the P1NP/βCTX ratios, while decreased DKK-1 and CathK production at different time points in most patient subsets. In the full cohort and in RA, baseline and/or 12-month bone mineral density (BMD) at multiple sites exerted inverse relationships with CRP and βCTX, and positive correlation with SOST. In AS, L2-4 BMD after 1-year biologic therapy inversely correlated with baseline βCTX, while femoral neck BMD rather showed inverse correlations with CRP. Conclusions: Anti-TNF therapy slowed down generalized bone loss, in association with clinical improvements, in both diseases. TNF blockade may enhance bone formation and suppress joint destruction. Anti-TNF therapy may act inversely on DKK-1 and SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS. Key Points • One-year anti-TNF therapy halted generalized bone loss in association with clinical improvement in arthritides. • Anti-TNF therapy may inversely act on DKK-1 and SOST. • Independent predictors of BMD were SOST and βCTX in RA, while CRP in AS.
- Subjects
BONE density; ANKYLOSING spondylitis; RHEUMATOID arthritis; PARATHYROIDECTOMY; BLOOD proteins; BONE growth; BIOTHERAPY; DUAL-energy X-ray absorptiometry
- Publication
Clinical Rheumatology, 2020, Vol 39, Issue 1, p167
- ISSN
0770-3198
- Publication type
Article
- DOI
10.1007/s10067-019-04771-3